Stockscreener 앱 받기
5.01
0.60%
-0.03
전일 마감가:
$5.04
열려 있는:
$5.05
하루 거래량:
1.17M
Relative Volume:
1.40
시가총액:
$268.47M
수익:
-
순이익/손실:
$-42.05M
주가수익비율:
-1.7766
EPS:
-2.82
순현금흐름:
$-35.26M
1주 성능:
-12.87%
1개월 성능:
-7.56%
6개월 성능:
+59.05%
1년 성능:
+8.21%
1일 변동 폭
$4.72
$5.11
1주일 범위
$4.72
$5.78
52주 변동 폭
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
명칭
Protara Therapeutics Inc
전화
646-844-0337
주소
345 PARK AVENUE SOUTH, NEW YORK, NY
TARA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.01 | 270.08M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 개시 | Piper Sandler | Overweight |
| 2025-04-16 | 개시 | Scotiabank | Sector Outperform |
| 2025-03-14 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-10 | 재개 | Guggenheim | Buy |
| 2021-06-04 | 개시 | H.C. Wainwright | Buy |
| 2021-02-17 | 개시 | Oppenheimer | Outperform |
| 2020-10-19 | 개시 | Cowen | Outperform |
| 2020-07-29 | 개시 | Guggenheim | Buy |
모두보기
Protara Therapeutics Inc 주식(TARA)의 최신 뉴스
Is Immatics NV a strong candidate for buy and hold2025 Major Catalysts & Intraday High Probability Setup Alerts - baoquankhu1.vn
CEO Change: What chart patterns are forming on Protara Therapeutics Inc2025 Market WrapUp & Weekly Market Pulse Updates - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Earnings Update: What is the cash position of Protara Therapeutics IncJuly 2025 Sector Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) down to US$264m market cap, but institutional owners may not be as affected after a year of 5.8% returns - simplywall.st
Weekly Trades: What makes Protara Therapeutics Inc stock attractive todayJuly 2025 Setups & Free AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Published on: 2026-01-14 06:06:18 - Bộ Nội Vụ
Protara, Ceribell rise on FDA breakthrough designations - MSN
Protara to report interim results from BCG-unresponsive trial in Q1 - Investing.com Nigeria
Protara Therapeutics (TARA) Anticipates Key Milestones by 2026 - GuruFocus
New cancer and rare disease trials to watch as Protara outlines 2026 goals - Stock Titan
Protara Therapeutics (NASDAQ:TARA) Research Coverage Started at Piper Sandler - Defense World
Protara Therapeutics (NASDAQ:TARA) Upgraded to Strong-Buy at Piper Sandler - MarketBeat
Revenue per share of Protara Therapeutics, Inc. – DUS:1KPA - TradingView — Track All Markets
Why Protara Therapeutics Inc. stock could see breakout soonPortfolio Performance Summary & Risk Adjusted Buy and Sell Alerts - Улправда
Sectors Review: Why Protara Therapeutics Inc. stock is recommended by analystsMarket Activity Summary & Fast Gaining Stock Strategy Reports - ulpravda.ru
Is Protara Therapeutics Inc. stock overvalued by current metricsMarket Movers & Free Expert Verified Stock Movement Alerts - ulpravda.ru
Protara Therapeutics completes $75 million stock offering - MSN
Can Protara Therapeutics Inc. stock attract ESG capital inflows2025 Volatility Report & Free Expert Approved Momentum Trade Ideas - Улправда
Why Protara Therapeutics Inc. stock is popular among millennialsJuly 2025 Closing Moves & Weekly Market Pulse Updates - ulpravda.ru
How strong is Protara Therapeutics Inc. stock revenue growthJuly 2025 Review & Expert Curated Trade Setups - ulpravda.ru
Should I hold or sell Protara Therapeutics Inc. stock in 2025Analyst Downgrade & Risk Adjusted Buy and Sell Alerts - Улправда
Is Protara Therapeutics Inc. stock in correction or buying zoneBull Run & Weekly Watchlist for Hot Stocks - ulpravda.ru
Why Protara Therapeutics Inc. stock is recommended by analysts2025 Price Action Summary & Technical Pattern Alert System - Улправда
Piper Sandler initiates Protera Therapeutics stock with Overweight rating By Investing.com - Investing.com Canada
Protara begins patient dosing in phase 3 trial for IV choline therapy - Investing.com Nigeria
Protara Therapeutics (TARA) Begins Phase 3 THRIVE-3 Trial for Ke - GuruFocus
TARA Stock Initiated with 'Overweight' Rating by Piper Sandler | - GuruFocus
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support - The Manila Times
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Trial tests first IV choline therapy for patients on long-term IV nutrition - Stock Titan
Why analysts recommend Protara Therapeutics Inc. (1KPA) stock2026 world cup usa national team semifinals young talents counter attacking expert forecast statistical analysis - ulpravda.ru
Why Protara Therapeutics Inc. stock could outperform in 20252026 world cup usa national team quarterfinals young talents high defensive line tactical prediction insights - Улправда
FDA grants breakthrough therapy designation to Protara’s LM treatment By Investing.com - Investing.com Nigeria
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Movement Recap: How strong is Protara Therapeutics Inc stock revenue growthJuly 2025 PostEarnings & Long-Term Capital Growth Strategies - moha.gov.vn
Protara Therapeutics updates on TARA-002 development - The Pharma Letter
Protara, CeriBell rise on FDA breakthrough designations (TARA:NASDAQ) - Seeking Alpha
Protara Therapeutics (TARA) Gains FDA Designations for TARA-002 - GuruFocus
FDA grants breakthrough therapy designation to Protara’s LM treatment - Investing.com
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations - The Manila Times
Protara Therapeutics’ TARA-002 Study: A Potential Game-Changer for Lymphatic Malformations - MSN
Levels Update: How forex fluctuations impact Protara Therapeutics Inc 1KPA stock2025 Historical Comparison & Fast Entry and Exit Trade Plans - moha.gov.vn
Assenagon Asset Management S.A. Invests $1.34 Million in Protara Therapeutics, Inc. $TARA - Defense World
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 - Sahm
Sentiment Watch: Can Protara Therapeutics Inc stock attract ESG capital inflows2025 EndofYear Setup & Weekly High Potential Stock Alerts - moha.gov.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Protara Therapeutics Inc (TARA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):